In this article, I will explain in concise analysis and plain English why Nuvation Bio Inc. (NYSE: NUVB ), which currently is in the early stage of marketing IBTROZI (taletrectinib), a TKI for ROS-1-positive NSCLC, approved by the FDA on June 11, 2025, is a rareI am a corporate lawyer with an MBA and a long-standing interest in value investing. After spending 7 years practicing at several prestigious Wall Street and Silicon Valley law firms as a corporate transactional lawyer, I founded and have been operat ...

In this article, I will explain in concise analysis and plain English why Nuvation Bio Inc. (NYSE: NUVB ), which currently is in the early stage of marketing IBTROZI (taletrectinib), a TKI for ROS-1-positive NSCLC, approved by the FDA on June 11, 2025, is a rareI am a corporate lawyer with an MBA and a long-standing interest in value investing. After spending 7 years practicing at several prestigious Wall Street and Silicon Valley law firms as a corporate transactional lawyer, I founded and have been operat ...